腹腔镜胃癌根治术对机体免疫功能及腹腔微转移的影响

摘要

目的 探讨腹腔镜胃癌根治术对机体免疫功能及腹腔微转移的影响.方法 以入院病例号为编号,根据随机数字表,将120例胃癌患者进行随机分组为实验组和对照组各60例.实验组患者实施腹腔镜根治术治疗,对照组患者实施传统开腹胃癌根治术,观察比较两组患者手术指标、应激炎性指标、免疫指标和微转移指标差异.结果 实验组患者出血量 (179.94±31.46) ml、切口长度 (5.12±2.78) cm、肠功能恢复时间 (54.97±10.36) h,治疗后CRP (13.96±3.45) μg/l、IL-6 (57.49±6.01) μg/l、IL-10 (231.74±21.94) pg/ml,CD4 (11.63±1.21) ％、CD8 (3.41±0.73) ％、CD4+/CD8+ (3.56±0.19),DDC (125.82±18.02) ng/ml、CEA (151.07±251.94) ng/ml,与对照组比较存在明显差异,差异具有统计学意义 (P ＜0.05).结论 腹腔镜手术治疗胃癌患者的近期临床疗效较好,对患者造成的机体创伤较小及对免疫功能的影响较小,同时患者术后发生微转移的风险较小,具有一定临床应用价值,且为腹腔镜手术在胃癌患者治疗中的广泛应用提供了有效依据.%Objective To investigate the effect of laparoscopic radical gastrectomy on immune function and peritoneal micrometastasis. Methods According to the number of hospitalized cases and the random number table, 120 patients with gastric cancer were randomly divided into experimental group and control group, 60 cases each. The patients in the experimental group were treated with laparoscopic radical mastectomy. The patients in the control group were treated by conventional open radical gastrectomy. The differences of surgical indexes, inflammatory inflammatory indexes, immune indexes and micrometastasis indexes were observed and compared between the two groups. Results The bleeding volume in the experimental group was (179.94 ±31.46) ml, the incision length was (5.12 ± 2.78) cm, the recovery time of intestinal function was (54.97 ± 10.36) h, and the CRP was (13.96 ± 3.45) μg/l and IL-6 (57.49 ± 6.01), IL-10 (231.74 ± 21.94) pg/ml, CD4 (11.63 ± 1.21) ％, CD8 (3.41± 0.73) ％, CD4+/CD8+ (3.56 ± 0.19), DDC (125.82 ± 18.02) ng/ml and CEA (151.07 ± 251.94) ng/ml, compared with the control group, the difference was statistically significant (P ＜ 0.05). Conclusion Laparoscopic surgery for the treatment of gastric cancer in patients with recent clinical efficacy is good, the patient caused less trauma and less impact on immune function, and patients with less risk of postoperative micrometastasis, has some clinical value and is the abdominal cavity Mirror surgery in the treatment of patients with gastric cancer provides a valid basis.